American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD).

[1]  K. Cusi,et al.  A global view of the interplay between non-alcoholic fatty liver disease and diabetes. , 2022, The lancet. Diabetes & endocrinology.

[2]  D. Bernstein,et al.  Noninvasive assessment of fibrosis among patients with nonalcoholic fatty liver disease [NAFLD] , 2022, Metabolism open.

[3]  E. Huang,et al.  10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2022. , 2021, Diabetes care.

[4]  Neil Murthy,et al.  Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older — United States, 2022 , 2014, MMWR. Morbidity and mortality weekly report.

[5]  A. Juuti,et al.  Obesity Modifies the Performance of Fibrosis Biomarkers in Nonalcoholic Fatty Liver Disease , 2021, The Journal of clinical endocrinology and metabolism.

[6]  J. Hjelmesæth,et al.  Gastric Bypass Versus Sleeve Gastrectomy in Type 2 Diabetes: Effects on Hepatic Steatosis and Fibrosis , 2021, Annals of Internal Medicine.

[7]  P. Schauer,et al.  Association of Bariatric Surgery With Major Adverse Liver and Cardiovascular Outcomes in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis. , 2021, JAMA.

[8]  B. Neuschwander‐Tetri,et al.  Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease. , 2021, The New England journal of medicine.

[9]  H. Sutanto,et al.  Reduction of Major Adverse Cardiovascular Events (MACE) after Bariatric Surgery in Patients with Obesity and Cardiovascular Diseases: A Systematic Review and Meta-Analysis , 2021, Nutrients.

[10]  K. Cusi,et al.  Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease , 2021, Obesity.

[11]  M. Orešič,et al.  Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests , 2021, Nature Reviews Gastroenterology & Hepatology.

[12]  Stanley Andrisse,et al.  Nonalcoholic Fatty Liver Disease in Women and Girls with Polycystic Ovary Syndrome. , 2021, The Journal of clinical endocrinology and metabolism.

[13]  C. Mantzoros,et al.  Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. , 2021, Gastroenterology.

[14]  K. Cusi,et al.  The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD , 2021, The Journal of clinical endocrinology and metabolism.

[15]  M. Karsdal,et al.  Biomarkers of extracellular matrix formation are associated with acute-on-chronic liver failure , 2021, JHEP reports : innovation in hepatology.

[16]  M. Bonacini,et al.  Racial differences in prevalence and severity of non-alcoholic fatty liver disease , 2021, World journal of hepatology.

[17]  C. Mantzoros,et al.  Preparing for the NASH Epidemic: A Call to Action , 2021, Diabetes Care.

[18]  Yulin Xiang,et al.  Effect of Intermittent Fasting on Non-Alcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis , 2021, Frontiers in Nutrition.

[19]  K. Cusi,et al.  PPAR‐γ‐induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH , 2021, Liver international : official journal of the International Association for the Study of the Liver.

[20]  M. Buti,et al.  A Global Survey of Physicians Knowledge About Non-alcoholic Fatty Liver Disease. , 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[21]  R. Biswas,et al.  Poor Awareness of Liver Disease Among Adults With NAFLD in the United States , 2021, Hepatology communications.

[22]  V. Wong,et al.  Defining comprehensive models of care for NAFLD , 2021, Nature Reviews Gastroenterology & Hepatology.

[23]  T. Kawaguchi,et al.  Effects of Mediterranean Diet in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-Analysis, and Meta-Regression Analysis of Randomized Controlled Trials , 2021, Seminars in Liver Disease.

[24]  M. Karsdal,et al.  Determining a healthy reference range and factors potentially influencing PRO-C3 – A biomarker of liver fibrosis , 2021, JHEP reports : innovation in hepatology.

[25]  K. Cusi,et al.  Severity of non-alcoholic steatohepatitis is not linked to testosterone concentration in patients with type 2 diabetes , 2021, PloS one.

[26]  Z. Younossi,et al.  The Burden of Nonalcoholic Fatty Liver Disease in Asia, Middle East and North Africa: Data from Global Burden of Disease 2009-2019. , 2021, Journal of hepatology.

[27]  V. Wong,et al.  Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis , 2021, Gut.

[28]  M. Roden,et al.  The complex link between NAFLD and type 2 diabetes mellitus — mechanisms and treatments , 2021, Nature Reviews Gastroenterology & Hepatology.

[29]  L. N. Valenti,et al.  Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: a systematic review and meta-analysis. , 2021, Journal of hepatology.

[30]  J. Ludvigsson,et al.  Cancer Risk in Patients With Biopsy‐Confirmed Nonalcoholic Fatty Liver Disease: A Population‐Based Cohort Study , 2021, Hepatology.

[31]  C. Hutton,et al.  Comparison between magnetic resonance and ultrasound-derived indicators of hepatic steatosis in a pooled NAFLD cohort , 2021, PloS one.

[32]  M. Mouzaki,et al.  Alternative Etiologies of Liver Disease in Children With Suspected NAFLD , 2021, Pediatrics.

[33]  F. Greenway,et al.  Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. , 2021, JAMA.

[34]  Jennifer M Aldridge Whitehead,et al.  Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort. , 2021, Journal of hepatology.

[35]  Matthew J. Crowley,et al.  Glycemic Control Predicts Severity of Hepatocyte Ballooning and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease , 2021, Hepatology.

[36]  A. Facciorusso,et al.  Systematic review with meta‐analysis: bariatric surgery reduces the incidence of hepatocellular carcinoma , 2021, Alimentary pharmacology & therapeutics.

[37]  C. Thompson,et al.  Effect of Endoscopic Bariatric and Metabolic Therapies on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. , 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[38]  T. Wadden,et al.  Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial , 2021, The Lancet.

[39]  T. Wadden,et al.  Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. , 2021, JAMA.

[40]  T. Brismar,et al.  Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet – a randomised controlled trial , 2021, JHEP reports : innovation in hepatology.

[41]  T. Sakae,et al.  Weight-loss-independent benefits of exercise on liver steatosis and stiffness in Japanese men with NAFLD , 2021, JHEP reports : innovation in hepatology.

[42]  T. Wadden,et al.  Once-Weekly Semaglutide in Adults with Overweight or Obesity. , 2021, The New England journal of medicine.

[43]  R. Weiskirchen,et al.  Fructose and Non-Alcoholic Steatohepatitis , 2021, Frontiers in Pharmacology.

[44]  R. Karagozian,et al.  The Clinical Impact of Cirrhosis on the Hospital Outcomes of Patients Admitted With Influenza Infection: Propensity Score Matched Analysis of 2011-2017 US Hospital Data. , 2021, Journal of clinical and experimental hepatology.

[45]  V. Wong,et al.  Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis. , 2021, The lancet. Gastroenterology & hepatology.

[46]  K. Cusi,et al.  Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening , 2020, Diabetes Care.

[47]  Robert Rohling,et al.  Three-Dimensional Multi-Frequency Shear Wave Absolute Vibro-Elastography (3D S-WAVE) With a Matrix Array Transducer: Implementation and Preliminary In Vivo Study of the Liver , 2020, IEEE Transactions on Medical Imaging.

[48]  J. Fallowfield,et al.  Correlations Between MRI Biomarkers PDFF and cT1 With Histopathological Features of Non-Alcoholic Steatohepatitis , 2021, Frontiers in Endocrinology.

[49]  Dandan Song,et al.  Association of non‐alcoholic fatty liver disease with diabetic retinopathy in type 2 diabetic patients: A meta‐analysis of observational studies , 2020, Journal of diabetes investigation.

[50]  G. Perseghin,et al.  High Prevalence of Advanced Liver Fibrosis Assessed by Transient Elastography Among U.S. Adults With Type 2 Diabetes , 2020, Diabetes Care.

[51]  V. Wong,et al.  The Association of Histologic and Non-invasive Tests with Adverse Clinical and Patient-Reported Outcomes in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis (NASH). , 2020, Gastroenterology.

[52]  Z. Younossi,et al.  AGA Clinical Practice Update on Lifestyle Modification Using Diet and Exercise to Achieve Weight Loss in the Management of Nonalcoholic Fatty Liver Disease (NAFLD): Expert Review. , 2020, Gastroenterology.

[53]  V. de Lédinghen,et al.  Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease. , 2020, Journal of hepatology.

[54]  H. Bajaj,et al.  Extended‐release naltrexone/bupropion and liver health: Pooled, post hoc analysis from four randomized controlled trials , 2020, Diabetes, obesity & metabolism.

[55]  R. Mekary,et al.  The Effect of Low-Fat and Low-Carbohydrate Diets on Weight Loss and Lipid Levels: A Systematic Review and Meta-Analysis , 2020, Nutrients.

[56]  K. Cusi,et al.  Cardiovascular risk in patients with nonalcoholic fatty liver disease: looking at the liver to shield the heart. , 2020, Current opinion in lipidology.

[57]  S. Jebb,et al.  The effect of the magnitude of weight loss on non-alcoholic fatty liver disease: a systematic review and meta-analysis. , 2020, Metabolism: clinical and experimental.

[58]  C. Mandelia,et al.  Performance Characteristics, Intra- & Inter-Operator Agreement of Transient Elastography in Pediatric NAFLD. , 2020, Journal of pediatric gastroenterology and nutrition.

[59]  Nitin Kumar,et al.  Association for Bariatric Endoscopy systematic review and meta-analysis assessing the American Society for Gastrointestinal Endoscopy Preservation and Incorporation of Valuable Endoscopic Innovations thresholds for aspiration therapy. , 2020, Gastrointestinal endoscopy.

[60]  K. Cusi,et al.  A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. , 2020, The New England journal of medicine.

[61]  A. Sahu,et al.  Safety of metabolic and bariatric surgery in obese patients with liver cirrhosis: a systematic review and meta-analysis. , 2020, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.

[62]  J. Ludvigsson,et al.  Mortality in Biopsy-Confirmed Nonalcoholic Fatty Liver Disease , 2020, Gut.

[63]  K. Cusi,et al.  Latin American Association for the Study of the Liver (ALEH) Practice Guidance for the Diagnosis and Treatment of Non-Alcoholic Fatty Liver Disease. , 2020, Annals of hepatology.

[64]  K. Cusi,et al.  Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease , 2020, Current Diabetes Reports.

[65]  L. Igel,et al.  Five-year outcomes of endoscopic sleeve gastroplasty for the treatment of obesity. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[66]  V. Wong,et al.  The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease , 2020, Hepatology International.

[67]  P. Bossuyt,et al.  Prognostic accuracy of FIB‐4, NAFLD fibrosis score and APRI for NAFLD‐related events: A systematic review , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[68]  H. Tilg,et al.  Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals , 2020, Gut.

[69]  A. Scheen.  Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus , 2020, Nature Reviews Endocrinology.

[70]  H. D. de Valk,et al.  Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) in Patients With Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis , 2020, The Journal of clinical endocrinology and metabolism.

[71]  Xue Fei Wang,et al.  Clinical spectrum of non-alcoholic fatty liver disease in patients with diabetes mellitus , 2020, PloS one.

[72]  M. Anvari,et al.  Association Between Bariatric Surgery and All-Cause Mortality: A Population-Based Matched Cohort Study in a Universal Health Care System , 2020, Annals of Internal Medicine.

[73]  L. Gerber,et al.  Contribution of sarcopenia and physical inactivity to mortality in people with non-alcoholic fatty liver disease , 2020, JHEP reports : innovation in hepatology.

[74]  D. Dieterich,et al.  Screening for Non-Alcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the U.S. is Cost Effective: A Comprehensive Cost-Utility Analysis. , 2020, Gastroenterology.

[75]  P. Bedossa,et al.  A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study. , 2020, The lancet. Gastroenterology & hepatology.

[76]  S. Neubauer,et al.  Prognostic value of multiparametric magnetic resonance imaging, transient elastography and blood‐based fibrosis markers in patients with chronic liver disease , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[77]  P. Beddy,et al.  Improvement in histological endpoints of MAFLD following a 12‐week aerobic exercise intervention , 2020, Alimentary pharmacology & therapeutics.

[78]  Kathryn J Fowler,et al.  Progression of Fatty Liver Disease in Children Receiving Standard of Care Lifestyle Advice. , 2020, Gastroenterology.

[79]  F. Klauschen,et al.  High‐protein diet more effectively reduces hepatic fat than low‐protein diet despite lower autophagy and FGF21 levels , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[80]  R. DeFronzo,et al.  Newly Discovered Abnormal Glucose Tolerance in Patients With Acute Myocardial Infarction and Cardiovascular Outcomes: A Meta-analysis , 2020, Diabetes Care.

[81]  R. Welbourn,et al.  Association of bariatric surgery with all-cause mortality and incidence of obesity-related disease at a population level: A systematic review and meta-analysis , 2020, PLoS medicine.

[82]  P. Thuluvath,et al.  Diabetes and Hepatocellular Carcinoma: Incidence Trends and Impact of Liver Disease Etiology. , 2020, Journal of clinical and experimental hepatology.

[83]  G. Koch,et al.  Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials. , 2020, Journal of hepatology.

[84]  O. Almohammed,et al.  Indirect comparison of glucagon like peptide-1 receptor agonists regarding cardiovascular safety and mortality in patients with type 2 diabetes mellitus: network meta-analysis , 2020, Cardiovascular Diabetology.

[85]  F. Pattou,et al.  Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis. , 2020, Gastroenterology.

[86]  G. Twig,et al.  Cardiovascular morbidity, diabetes and cancer risk among children and adolescents with severe obesity , 2020, Cardiovascular Diabetology.

[87]  V. Wong,et al.  Identification of Patients with Advanced Fibrosis Due to Nonalcoholic Fatty Liver Disease: Considerations for Best Practice. , 2020, Journal of gastrointestinal and liver diseases : JGLD.

[88]  C. Stave,et al.  Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. , 2020, The lancet. Gastroenterology & hepatology.

[89]  M. Clark,et al.  Intragastric Balloon Placement Induces Significant Metabolic and Histologic Improvement in Patients With Nonalcoholic Steatohepatitis. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[90]  G. Pantuso,et al.  The Prevalence of NAFLD and Fibrosis in Bariatric Surgery Patients and the Reliability of Noninvasive Diagnostic Methods , 2020, BioMed research international.

[91]  H. Tilg,et al.  NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications , 2020, Gut.

[92]  P. Bossuyt,et al.  Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis. , 2020, Journal of hepatology.

[93]  G. Kaplan,et al.  Risk stratification of patients with nonalcoholic fatty liver disease using a case identification pathway in primary care: a cross-sectional study. , 2020, CMAJ open.

[94]  I. Sporea,et al.  Screening for Liver Fibrosis and Steatosis in a Large Cohort of Patients with Type 2 Diabetes Using Vibration Controlled Transient Elastography and Controlled Attenuation Parameter in a Single-Center Real-Life Experience , 2020, Journal of clinical medicine.

[95]  P. Hale,et al.  A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity. , 2020, The New England journal of medicine.

[96]  B. Nordestgaard,et al.  Combined Effect of PNPLA3, TM6SF2, and HSD17B13 Variants on Risk of Cirrhosis and Hepatocellular Carcinoma in the General Population , 2020, Hepatology.

[97]  T. Hornemann,et al.  Intrahepatic Fat and Postprandial Glycemia Increase After Consumption of a Diet Enriched in Saturated Fat Compared With Free Sugars , 2020, Diabetes Care.

[98]  A. McCullough,et al.  Accuracy of Noninvasive Fibrosis Scores to Detect Advanced Fibrosis in Patients With Type-2 Diabetes With Biopsy-proven Nonalcoholic Fatty Liver Disease , 2020, Journal of clinical gastroenterology.

[99]  E. Kang,et al.  Nonalcoholic Fatty Liver Disease and Sarcopenia Are Independently Associated With Cardiovascular Risk. , 2020, The American journal of gastroenterology.

[100]  C. Byrne,et al.  NAFLD as a driver of chronic kidney disease. , 2020, Journal of hepatology.

[101]  Z. Younossi,et al.  Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD , 2020, Hepatology.

[102]  M. Farkouh,et al.  Cardiometabolic-Based Chronic Disease, Adiposity and Dysglycemia Drivers: JACC State-of-the-Art Review. , 2020, Journal of the American College of Cardiology.

[103]  N. Bhala,et al.  Association Between Fibrosis Stage and Outcomes of Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis. , 2020, Gastroenterology.

[104]  L. Kelly,et al.  Intermittent fasting and weight loss: Systematic review. , 2020, Canadian family physician Medecin de famille canadien.

[105]  V. Wong,et al.  Serial Transient Elastography Examinations to Monitor Patients With Type 2 Diabetes: A Prospective Cohort Study , 2020, Hepatology.

[106]  K. Cusi.  Time to Include Nonalcoholic Steatohepatitis in the Management of Patients With Type 2 Diabetes , 2020, Diabetes Care.

[107]  A. Sanyal,et al.  Leveraging Human Genetics to Identify Potential New Treatments for Fatty Liver Disease. , 2020, Cell metabolism.

[108]  S. Asch,et al.  Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Nonalcoholic Fatty Liver Disease , 2020, Hepatology.

[109]  N. Terrault,et al.  Polycystic ovary syndrome (PCOS) is associated with NASH severity and advanced fibrosis , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[110]  K. Birkeland,et al.  Gastric bypass versus sleeve gastrectomy in patients with type 2 diabetes (Oseberg): a single-centre, triple-blind, randomised controlled trial. , 2019, The lancet. Diabetes & endocrinology.

[111]  G. Lippi,et al.  Screening for non-alcoholic fatty liver disease using liver stiffness measurement and its association with chronic kidney disease and cardiovascular complications in patients with type 2 diabetes. , 2019, Diabetes & metabolism.

[112]  Robert P. Myers,et al.  Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials , 2019, Hepatology.

[113]  Myeong Jun Song,et al.  Optimizing Use of Nonalcoholic Fatty Liver Disease Fibrosis Score, Fibrosis-4 Score, and Liver Stiffness Measurement to Identify Patients With Advanced Fibrosis. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[114]  Z. Younossi,et al.  Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the U.S. , 2019, Diabetes Care.

[115]  K. Cusi,et al.  Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes , 2019, Diabetes Care.

[116]  W. Zhou,et al.  Effects of alternate-day fasting on body weight and dyslipidaemia in patients with non-alcoholic fatty liver disease: a randomised controlled trial , 2019, BMC Gastroenterology.

[117]  J. Martínez,et al.  The Metabolic and Hepatic Impact of Two Personalized Dietary Strategies in Subjects with Obesity and Nonalcoholic Fatty Liver Disease: The Fatty Liver in Obesity (FLiO) Randomized Controlled Trial , 2019, Nutrients.

[118]  O. Cummings,et al.  Histologic Findings of Advanced Fibrosis and Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Who Have Normal Aminotransferase Levels. , 2019, The American journal of gastroenterology.

[119]  Z. Younossi,et al.  The Global Epidemiology of NAFLD and NASH in Patients with type 2 diabetes: A Systematic Review and Meta-analysis. , 2019, Journal of hepatology.

[120]  N. Stefan,et al.  Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial , 2019, Diabetes Care.

[121]  A. Gangemi,et al.  Systematic review and meta-analysis of Roux-en-Y gastric bypass against laparoscopic sleeve gastrectomy for amelioration of NAFLD using four criteria. , 2019, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.

[122]  M. Kattan,et al.  Association of Metabolic Surgery With Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes and Obesity. , 2019, JAMA.

[123]  Jeong Hwan Park,et al.  Nonalcoholic steatohepatitis is associated with a higher risk of advanced colorectal neoplasm , 2019, Liver international : official journal of the International Association for the Study of the Liver.

[124]  J. McCall,et al.  Prevalence of diabetes in liver cirrhosis: A systematic review and meta‐analysis , 2019, Diabetes/metabolism research and reviews.

[125]  L. Henry,et al.  Mortality Related to Nonalcoholic Fatty Liver Disease Is Increasing in the United States , 2019, Hepatology communications.

[126]  L. Longworth,et al.  Referral pathways for patients with NAFLD based on non‐invasive fibrosis tests: Diagnostic accuracy and cost analysis , 2019, Liver international : official journal of the International Association for the Study of the Liver.

[127]  Z. Ma,et al.  A Randomised Controlled Trial on the Effectiveness and Adherence of Modified Alternate-day Calorie Restriction in Improving Activity of Non-Alcoholic Fatty Liver Disease , 2019, Scientific Reports.

[128]  J. Borén,et al.  Overeating Saturated Fat Promotes Fatty Liver and Ceramides Compared With Polyunsaturated Fat: A Randomized Trial , 2019, The Journal of clinical endocrinology and metabolism.

[129]  V. de Lédinghen,et al.  New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD. , 2019, Journal of hepatology.

[130]  Michal Rein,et al.  The beneficial effects of Mediterranean diet over low-fat diet may be mediated by decreasing hepatic fat content. , 2019, Journal of hepatology.

[131]  D. Thorburn,et al.  Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease. , 2019, Journal of hepatology.

[132]  Christopher J. N. Kigongo,et al.  Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[133]  M. Stepanova,et al.  Epidemiology of chronic liver diseases in the USA in the past three decades , 2019, Gut.

[134]  L. Sharples,et al.  A systematic review and meta‐analysis estimating the population prevalence of comorbidities in children and adolescents aged 5 to 18 years , 2019, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[135]  K. Cusi,et al.  From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options , 2019, JHEP reports.

[136]  W. Rosenberg,et al.  Cost-comparison analysis of FIB-4, ELF and fibroscan in community pathways for non-alcoholic fatty liver disease , 2019, BMC Gastroenterology.

[137]  K. Cusi,et al.  Nonalcoholic Fatty Liver Disease: The Overlooked Complication of Type 2 Diabetes , 2019 .

[138]  Guy Cloutier,et al.  Prospective comparison of transient, point shear wave, and magnetic resonance elastography for staging liver fibrosis , 2019, European Radiology.

[139]  Elizabeth Morris,et al.  Association of Weight Loss Interventions With Changes in Biomarkers of Nonalcoholic Fatty Liver Disease , 2019, JAMA internal medicine.

[140]  M. Armstrong,et al.  Evaluations of Lifestyle, Dietary, and Pharmacologic Treatments for Pediatric Nonalcoholic Fatty Liver Disease: A Systematic Review. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[141]  Donglie Zhu,et al.  Insulin-like growth factor-1 and non-alcoholic fatty liver disease: a systemic review and meta-analysis , 2019, Endocrine.

[142]  V. de Lédinghen,et al.  Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients With Nonalcoholic Fatty Liver Disease. , 2019, The American journal of gastroenterology.

[143]  K. Cusi.  Incretin‐Based Therapies for the Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes , 2019, Hepatology.

[144]  M. Karsdal,et al.  Use of Plasma Fragments of Propeptides of Type III, V, and VI Procollagen for the Detection of Liver Fibrosis in Type 2 Diabetes , 2019, Diabetes Care.

[145]  A. Courcoulas,et al.  Five-Year Outcomes of Gastric Bypass in Adolescents as Compared with Adults. , 2019, The New England journal of medicine.

[146]  K. Cusi,et al.  Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial , 2019, Diabetes Care.

[147]  M. Anvari,et al.  Complete Resolution of Nonalcoholic Fatty Liver Disease After Bariatric Surgery: A Systematic Review and Meta‐analysis , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[148]  R. Holman,et al.  A multidisciplinary approach to the management of NAFLD is associated with improvement in markers of liver and cardio-metabolic health , 2019, Frontline Gastroenterology.

[149]  W. Tamborlane,et al.  Liraglutide in Children and Adolescents with Type 2 Diabetes. , 2019, The New England journal of medicine.

[150]  A. Lonardo,et al.  Pathogenesis of hypothyroidism-induced NAFLD: Evidence for a distinct disease entity? , 2019, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[151]  M. Plauth,et al.  ESPEN guideline on clinical nutrition in liver disease. , 2019, Clinical nutrition.

[152]  Rohit Loomba,et al.  Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. , 2019, Gastroenterology.

[153]  H. Tilg,et al.  Association between non‐alcoholic fatty liver disease and risk of atrial fibrillation in adult individuals: An updated meta‐analysis , 2019, Liver international : official journal of the International Association for the Study of the Liver.

[154]  K. Cusi,et al.  Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. , 2019, The lancet. Diabetes & endocrinology.

[155]  Yun-gen Gan,et al.  Accuracy of multi-echo Dixon sequence in quantification of hepatic steatosis in Chinese children and adolescents , 2019, World journal of gastroenterology.

[156]  T. Lehtimäki,et al.  The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients , 2019, Diabetes Care.

[157]  K. Cusi,et al.  Re: "Association Between Primary Hypothyroidism and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis" by Mantovani et al. (Thyroid 2018;28:1270-1284). , 2019, Thyroid : official journal of the American Thyroid Association.

[158]  D. Bruttomesso,et al.  Vitamin D status and non-alcoholic fatty liver disease in patients with type 1 diabetes , 2019, Journal of Endocrinological Investigation.

[159]  J. Hebebrand,et al.  The ABCD of Obesity: An EASO Position Statement on a Diagnostic Term with Clinical and Scientific Implications , 2019, Obesity Facts.

[160]  E. Muradova,et al.  Bariatric surgery improves nonalcoholic fatty liver disease: a contemporary systematic review and meta-analysis. , 2019, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.

[161]  V. Wong,et al.  Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[162]  M. Rubenfire,et al.  Impact of a structured lifestyle programme on patients with metabolic syndrome complicated by non‐alcoholic fatty liver disease , 2018, Alimentary pharmacology & therapeutics.

[163]  Z. Younossi,et al.  Race/ethnicity-based temporal changes in prevalence of NAFLD-related advanced fibrosis in the United States, 2005–2016 , 2019, Hepatology International.

[164]  M. Allison,et al.  Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. , 2019, Gastroenterology.

[165]  C. Sirlin,et al.  Effect of a Low Free Sugar Diet vs Usual Diet on Nonalcoholic Fatty Liver Disease in Adolescent Boys: A Randomized Clinical Trial , 2019, JAMA.

[166]  P. Hale,et al.  Liraglutide effects in a paediatric (7‐11 y) population with obesity: A randomized, double‐blind, placebo‐controlled, short‐term trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics , 2019, Pediatric obesity.

[167]  B. Neuschwander‐Tetri,et al.  Vibration‐Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[168]  K. Khunti,et al.  Causality between non‐alcoholic fatty liver disease and risk of cardiovascular disease and type 2 diabetes: A meta‐analysis with bias analysis , 2018, Liver international : official journal of the International Association for the Study of the Liver.

[169]  N. Veronese,et al.  Reducing NAFLD‐screening time: A comparative study of eight diagnostic methods offering an alternative to ultrasound scans , 2018, Liver international : official journal of the International Association for the Study of the Liver.

[170]  R. Hultcrantz,et al.  Cardiovascular risk factors in non‐alcoholic fatty liver disease , 2018, Liver international : official journal of the International Association for the Study of the Liver.

[171]  O. Cummings,et al.  Vitamin E Improves Transplant‐Free Survival and Hepatic Decompensation Among Patients With Nonalcoholic Steatohepatitis and Advanced Fibrosis , 2020, Hepatology.

[172]  D. Jun,et al.  Critical appraisal for low-carbohydrate diet in nonalcoholic fatty liver disease: Review and meta-analyses. , 2019, Clinical nutrition.

[173]  H. Kirikoshi,et al.  Distribution of liver stiffness in non‐alcoholic fatty liver disease with higher fibrosis‐4 index than low cut‐off index , 2019, Journal of gastroenterology and hepatology.

[174]  S. Mudaliar,et al.  Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes , 2019, Diabetes, obesity & metabolism.

[175]  Nik Raihan Nik Mustapha,et al.  Screening for non‐alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography , 2018, Journal of gastroenterology and hepatology.

[176]  Z. Goodman,et al.  The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options. , 2018, Journal of hepatology.

[177]  S. Pungpapong,et al.  Association between diastolic cardiac dysfunction and nonalcoholic fatty liver disease: A systematic review and meta-analysis. , 2018, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[178]  J. Sherriff,et al.  Ad Libitum Mediterranean and Low‐Fat Diets Both Significantly Reduce Hepatic Steatosis: A Randomized Controlled Trial , 2018, Hepatology.

[179]  C. Mantzoros,et al.  Association Between Primary Hypothyroidism and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. , 2018, Thyroid : official journal of the American Thyroid Association.

[180]  M. Kumar,et al.  Range of Normal Liver stiffness and Predictors of Suspected Advanced Fibrosis in Apparently Healthy Individuals: A Pooled Analysis of 16,082 Participants , 2018 .

[181]  L. Gray,et al.  The effect of exercise training on intrahepatic triglyceride and hepatic insulin sensitivity: a systematic review and meta‐analysis , 2018, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[182]  H. Ran,et al.  Diagnostic accuracy of point shear wave elastography and transient elastography for staging hepatic fibrosis in patients with non-alcoholic fatty liver disease: a meta-analysis , 2018, BMJ Open.

[183]  Antonio Felix Conde-Martin,et al.  Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study. , 2018, Gastroenterology.

[184]  D. Maahs,et al.  Obesity in Type 1 Diabetes: Pathophysiology, Clinical Impact, and Mechanisms. , 2018, Endocrine reviews.

[185]  Jiang Cao,et al.  Efficacy of orlistat in non-alcoholic fatty liver disease: A systematic review and meta-analysis. , 2018, Biomedical reports.

[186]  D. Levy,et al.  Improved Diet Quality Associates With Reduction in Liver Fat, Particularly in Individuals With High Genetic Risk Scores for Nonalcoholic Fatty Liver Disease. , 2018, Gastroenterology.

[187]  Mohammed K. Ali,et al.  Global Diabetes Prevention Interventions: A Systematic Review and Network Meta-analysis of the Real-World Impact on Incidence, Weight, and Glucose , 2018, Diabetes Care.

[188]  Jia Wu,et al.  A potential link between polycystic ovary syndrome and non-alcoholic fatty liver disease: an update meta-analysis , 2018, Reproductive Health.

[189]  T. Saibara,et al.  The novel cutoff points for the FIB4 index categorized by age increase the diagnostic accuracy in NAFLD: a multi-center study , 2018, Journal of Gastroenterology.

[190]  A. Kasprzak,et al.  Insulin-Like Growth Factor (IGF) System in Liver Diseases , 2018, International journal of molecular sciences.

[191]  Marju Orho-Melander,et al.  Saturated Fat Is More Metabolically Harmful for the Human Liver Than Unsaturated Fat or Simple Sugars , 2018, Diabetes Care.

[192]  M. Camilleri,et al.  Effects of Weight-Loss Medications on Cardiometabolic Risk Profiles: A Systematic Review and Network Meta-analysis. , 2018, Gastroenterology.

[193]  A. Coomarasamy,et al.  Polycystic ovary syndrome, androgen excess, and the risk of nonalcoholic fatty liver disease in women: A longitudinal study based on a United Kingdom primary care database , 2018, PLoS medicine.

[194]  Z. Younossi,et al.  Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD) , 2018, Medicine.

[195]  C. Sirlin,et al.  Diagnostic accuracy of magnetic resonance imaging hepatic proton density fat fraction in pediatric nonalcoholic fatty liver disease , 2018, Hepatology.

[196]  C J Kelly,et al.  Utility and cost evaluation of multiparametric magnetic resonance imaging for the assessment of non‐alcoholic fatty liver disease , 2018, Alimentary pharmacology & therapeutics.

[197]  I. Macdonald,et al.  Effects of sprint interval training on ectopic lipids and tissue-specific insulin sensitivity in men with non-alcoholic fatty liver disease , 2018, European Journal of Applied Physiology.

[198]  I. Janssen,et al.  Aspiration Therapy As a Tool to Treat Obesity: 1- to 4-Year Results in a 201-Patient Multi-Center Post-Market European Registry Study , 2018, Obesity Surgery.

[199]  E. Bonora,et al.  Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis. , 2018, Metabolism: clinical and experimental.

[200]  D. Schuppan,et al.  Determinants of fibrosis progression and regression in NASH. , 2018, Journal of hepatology.

[201]  C. Byrne,et al.  Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus , 2018, Nature Reviews Endocrinology.

[202]  Irl B Hirsch,et al.  AACE/ACE Consensus Statement CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM – 2018 EXECUTIVE SUMMARY , 2018 .

[203]  Avis J. Thomas,et al.  Lifestyle Intervention and Medical Management With vs Without Roux-en-Y Gastric Bypass and Control of Hemoglobin A1c, LDL Cholesterol, and Systolic Blood Pressure at 5 Years in the Diabetes Surgery Study , 2018, JAMA.

[204]  E. Bonora,et al.  Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: A Meta-analysis , 2018, Diabetes Care.

[205]  V. Pīrāgs,et al.  Fatty liver index and hepatic steatosis index for prediction of non‐alcoholic fatty liver disease in type 1 diabetes , 2018, Journal of gastroenterology and hepatology.

[206]  Michael Charlton,et al.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases , 2018, Hepatology.

[207]  B. Neuschwander‐Tetri,et al.  Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis , 2017, Hepatology.

[208]  Rohit Loomba,et al.  Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease , 2017, Hepatology.

[209]  Byung Gyu Kim,et al.  Association between non-alcoholic fatty liver disease and subclinical coronary atherosclerosis: An observational cohort study. , 2017, Journal of hepatology.

[210]  J. Browning,et al.  Racial and Ethnic Disparities in Nonalcoholic Fatty Liver Disease Prevalence, Severity, and Outcomes in the United States: A Systematic Review and Meta‐analysis , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[211]  Y. Liu,et al.  Energy-matched moderate and high intensity exercise training improves nonalcoholic fatty liver disease risk independent of changes in body mass or abdominal adiposity - A randomized trial. , 2018, Metabolism: clinical and experimental.

[212]  M. Ziol,et al.  Concomitant screening for liver fibrosis and steatosis in French type 2 diabetic patients using Fibroscan , 2017, Liver international : official journal of the International Association for the Study of the Liver.

[213]  R. Hultcrantz,et al.  Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. , 2017, Journal of hepatology.

[214]  Lunan Yan,et al.  Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta‐analysis , 2017, Hepatology.

[215]  B. Hoogwerf,et al.  Non‐alcoholic fatty liver disease (NAFLD) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes , 2017, Diabetes, obesity & metabolism.

[216]  Alexandra N. Schlein,et al.  Magnetic resonance elastography measured shear stiffness as a biomarker of fibrosis in pediatric nonalcoholic fatty liver disease , 2017, Hepatology.

[217]  R. Wong,et al.  Significant burden of nonalcoholic fatty liver disease with advanced fibrosis in the US: a cross‐sectional analysis of 2011‐2014 National Health and Nutrition Examination Survey , 2017, Alimentary pharmacology & therapeutics.

[218]  Manuel Romero-Gómez,et al.  Treatment of NAFLD with diet, physical activity and exercise. , 2017, Journal of hepatology.

[219]  J. George,et al.  Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: An age‐dependent risk profiling study , 2017, Liver international : official journal of the International Association for the Study of the Liver.

[220]  J. Garber,et al.  AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY PROTOCOL FOR STANDARDIZED PRODUCTION OF CLINICAL PRACTICE GUIDELINES, ALGORITHMS, AND CHECKLISTS - 2017 UPDATE. , 2017, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[221]  A. Unalp‐Arida,et al.  Liver fibrosis scores predict liver disease mortality in the United States population , 2017, Hepatology.

[222]  K. Kalinov,et al.  Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis , 2017, Diabetes Therapy.

[223]  V. Paradis,et al.  Controlled Attenuation Parameter (CAP) with the XL Probe of the Fibroscan®: A Comparative Study with the M Probe and Liver Biopsy , 2017, Digestive Diseases and Sciences.

[224]  R. Ehman,et al.  Diagnostic Performance of MR Elastography and Vibration-controlled Transient Elastography in the Detection of Hepatic Fibrosis in Patients with Severe to Morbid Obesity. , 2017, Radiology.

[225]  E. Paschetta,et al.  Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis , 2017, JAMA internal medicine.

[226]  D. Carey,et al.  Gastric Bypass Surgery Produces a Durable Reduction in Cardiovascular Disease Risk Factors and Reduces the Long‐Term Risks of Congestive Heart Failure , 2017, Journal of the American Heart Association.

[227]  W. Garvey,et al.  Cardiometabolic Disease Staging Predicts Effectiveness of Weight-Loss Therapy to Prevent Type 2 Diabetes: Pooled Results From Phase III Clinical Trials Assessing Phentermine/Topiramate Extended Release , 2017, Diabetes Care.

[228]  Jonathan C. Cohen,et al.  Adiposity Amplifies the Genetic Risk of Fatty Liver Disease Conferred by Multiple Loci , 2017, Nature Genetics.

[229]  M. Kroh,et al.  Safety and efficacy of bariatric surgery in patients with advanced fibrosis , 2017, International Journal of Obesity.

[230]  J. Mechanick,et al.  ADIPOSITY-BASED CHRONIC DISEASE AS A NEW DIAGNOSTIC TERM: THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT. , 2017, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[231]  D. Häussinger,et al.  Screening for non-alcoholic fatty liver disease in children and adolescents with type 1 diabetes mellitus: a cross-sectional analysis , 2017, European Journal of Pediatrics.

[232]  Deepak L. Bhatt,et al.  Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5‐Year Outcomes , 2017, The New England journal of medicine.

[233]  K. Cusi,et al.  Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action , 2017, Diabetes Care.

[234]  S. Liangpunsakul,et al.  The Association Between Nonalcoholic Fatty Liver Disease and Metabolic Abnormalities in The United States Population , 2017, Journal of clinical gastroenterology.

[235]  J. Machann,et al.  Isocaloric Diets High in Animal or Plant Protein Reduce Liver Fat and Inflammation in Individuals With Type 2 Diabetes. , 2017, Gastroenterology.

[236]  O. Kordonouri,et al.  Liraglutide in an Adolescent Population with Obesity: A Randomized, Double‐Blind, Placebo‐Controlled 5‐Week Trial to Assess Safety, Tolerability, and Pharmacokinetics of Liraglutide in Adolescents Aged 12‐17 Years , 2017, The Journal of pediatrics.

[237]  C. McKenzie,et al.  Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial. , 2017, World journal of gastroenterology.

[238]  Roy Taylor,et al.  Exercise Reduces Liver Lipids and Visceral Adiposity in Patients With Nonalcoholic Steatohepatitis in a Randomized Controlled Trial , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[239]  M. Allison,et al.  Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis , 2016, The American Journal of Gastroenterology.

[240]  M. Chang,et al.  Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis. , 2017, Journal of hepatology.

[241]  G. Silecchia,et al.  The Benefit of Sleeve Gastrectomy in Obese Adolescents on Nonalcoholic Steatohepatitis and Hepatic Fibrosis , 2017, The Journal of pediatrics.

[242]  T. Kawaguchi,et al.  Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review. , 2017, Journal of hepatology.

[243]  Stanley M. Cohen,et al.  ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries , 2017, The American Journal of Gastroenterology.

[244]  G. Lippi,et al.  Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular disease in adult patients with type 1 diabetes. , 2016, International journal of cardiology.

[245]  Robert M. Anderson,et al.  5. Prevention or Delay of Type 2 Diabetes , 2016, Diabetes Care.

[246]  B. Neuschwander‐Tetri,et al.  In Children With Nonalcoholic Fatty Liver Disease, Cysteamine Bitartrate Delayed Release Improves Liver Enzymes but Does Not Reduce Disease Activity Scores. , 2016, Gastroenterology.

[247]  F. Greenway,et al.  Early Weight Loss with Liraglutide 3.0 mg Predicts 1‐Year Weight Loss and is Associated with Improvements in Clinical Markers , 2016, Obesity.

[248]  E. Livingston,et al.  Bariatric Surgery and Long-term Durability of Weight Loss. , 2016, JAMA surgery.

[249]  C. Catalano,et al.  Comparison of magnetic resonance spectroscopy, proton density fat fraction and histological analysis in the quantification of liver steatosis in children and adolescents , 2016, World journal of gastroenterology.

[250]  A. Chang,et al.  Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes , 2016, Diabetes, obesity & metabolism.

[251]  P. Morel,et al.  Exercise-based Interventions for Nonalcoholic Fatty Liver Disease: A Meta-analysis and Meta-regression. , 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[252]  Lawrence A Leiter,et al.  Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. , 2016, The New England journal of medicine.

[253]  P. Pouwels,et al.  Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial , 2016, Diabetologia.

[254]  Pioglitazone is equally effective for diabetes prevention in older versus younger adults with impaired glucose tolerance , 2016, AGE.

[255]  E. Gregg.  Association of the Magnitude of Weight Loss and Physical Fitness Change on Long-term CVD outcomes: The Look AHEAD Study , 2016, The lancet. Diabetes & endocrinology.

[256]  N. Alkhouri,et al.  Plasma Cytokeratin-18 Level As a Novel Biomarker for Liver Fibrosis in Children With Nonalcoholic Fatty Liver Disease , 2016, Journal of pediatric gastroenterology and nutrition.

[257]  K. Cusi,et al.  Pharmacological management of nonalcoholic fatty liver disease. , 2016, Metabolism: clinical and experimental.

[258]  Jiang He,et al.  Effects of Moderate and Vigorous Exercise on Nonalcoholic Fatty Liver Disease: A Randomized Clinical Trial. , 2016, JAMA internal medicine.

[259]  K. Kowdley,et al.  Comparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD) , 2016, Medicine.

[260]  D. Brenner,et al.  Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial. , 2016, Journal of hepatology.

[261]  K. Furie,et al.  Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease , 2016, Diabetes Care.

[262]  L. Gerber,et al.  Effectiveness of exercise in hepatic fat mobilization in non-alcoholic fatty liver disease: Systematic review. , 2016, World journal of gastroenterology.

[263]  L. Henry,et al.  Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.

[264]  R. Plodkowski,et al.  AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY. , 2016, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[265]  J. Hardies,et al.  Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus , 2016, Annals of Internal Medicine.

[266]  John B Buse,et al.  Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. , 2016, The New England journal of medicine.

[267]  D. Goff,et al.  Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study , 2016, Diabetes Care.

[268]  S. Friedman,et al.  Development and validation of a noninvasive prediction model for nonalcoholic steatohepatitis resolution after lifestyle intervention , 2016, Hepatology.

[269]  E. Bonora,et al.  Nonalcoholic Fatty Liver Disease Is Associated With Ventricular Arrhythmias in Patients With Type 2 Diabetes Referred for Clinically Indicated 24-Hour Holter Monitoring , 2016, Diabetes Care.

[270]  L. Beilin,et al.  Adverse metabolic phenotype of adolescent girls with non‐alcoholic fatty liver disease plus polycystic ovary syndrome compared with other girls and boys , 2016, Journal of gastroenterology and hepatology.

[271]  A. Roverato,et al.  Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta‐analysis , 2016, Journal of gastroenterology and hepatology.

[272]  H. Tilg,et al.  EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. , 2016, Journal of hepatology.

[273]  S. Farshbaf,et al.  The effects of DASH diet on weight loss and metabolic status in adults with non‐alcoholic fatty liver disease: a randomized clinical trial , 2016, Liver international : official journal of the International Association for the Study of the Liver.

[274]  M. Chonchol,et al.  NAFLD and Chronic Kidney Disease , 2016, International journal of molecular sciences.

[275]  Xin Sun,et al.  Effects of Bariatric Surgery on Mortality, Cardiovascular Events, and Cancer Outcomes in Obese Patients: Systematic Review and Meta-analysis , 2016, Obesity Surgery.

[276]  S. Upala,et al.  Significant Association Between Gallstone Disease and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis , 2016, Digestive Diseases and Sciences.

[277]  S. Anderson,et al.  Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis , 2016, The Lancet.

[278]  T. Yamanaka,et al.  Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography. , 2016, Gastroenterology.

[279]  Bo Carlberg,et al.  Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses , 2016 .

[280]  D. Tanné,et al.  Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. , 2016, The New England journal of medicine.

[281]  Rachel M. Brown,et al.  Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study , 2016, The Lancet.

[282]  K. Cusi,et al.  Metabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients With Type 2 Diabetes , 2016, Diabetes Care.

[283]  H. El‐Serag,et al.  Trends in the Burden of Nonalcoholic Fatty Liver Disease in a United States Cohort of Veterans. , 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[284]  Rohit Loomba,et al.  Magnetic resonance elastography is superior to acoustic radiation force impulse for the Diagnosis of fibrosis in patients with biopsy‐proven nonalcoholic fatty liver disease: A prospective study , 2016, Hepatology.

[285]  J. Skelton,et al.  Physical Examination Findings Among Children and Adolescents With Obesity: An Evidence-Based Review , 2016, Pediatrics.

[286]  C. Sirlin,et al.  Non‐invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE , 2016, Alimentary pharmacology & therapeutics.

[287]  A. Hofman,et al.  Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: The Rotterdam study , 2016, Hepatology.

[288]  Jimmy D Bell,et al.  Dissociation between exercise-induced reduction in liver fat and changes in hepatic and peripheral glucose homoeostasis in obese patients with non-alcoholic fatty liver disease. , 2016, Clinical science.

[289]  C. Bonfiglio,et al.  Effect of a low glycemic index Mediterranean diet on non-alcoholic fatty liver disease. A randomized controlled clinici trial , 2016, The journal of nutrition, health & aging.

[290]  K. Cusi,et al.  Plasma thyroid hormone concentration is associated with hepatic triglyceride content in patients with type 2 diabetes , 2015, Journal of Investigative Medicine.

[291]  D. Hadjidakis,et al.  Increased prevalence of polycystic ovary syndrome in premenopausal women with nonalcoholic fatty liver disease. , 2015, European journal of endocrinology.

[292]  D. Lawlor,et al.  The Prevalence of Non-Alcoholic Fatty Liver Disease in Children and Adolescents: A Systematic Review and Meta-Analysis , 2015, PloS one.

[293]  Minqian Shen,et al.  Sex Hormones and Their Receptors Regulate Liver Energy Homeostasis , 2015, International journal of endocrinology.

[294]  A. Gamst,et al.  Intra- and inter-examination repeatability of magnetic resonance spectroscopy, magnitude-based MRI, and complex-based MRI for estimation of hepatic proton density fat fraction in overweight and obese children and adults , 2015, Abdominal Imaging.

[295]  J. Hardies,et al.  Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[296]  J. Boucher,et al.  Lifestyle weight-loss intervention outcomes in overweight and obese adults with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials. , 2015, Journal of the Academy of Nutrition and Dietetics.

[297]  S. Friedman,et al.  Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. , 2015, Gastroenterology.

[298]  F. Pattou,et al.  Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients. , 2015, Gastroenterology.

[299]  Å. Lernmark,et al.  Magnetic resonance imaging reveals altered distribution of hepatic fat in children with type 1 diabetes compared to controls. , 2015, Metabolism: clinical and experimental.

[300]  C. Fox,et al.  Hepatic steatosis and cardiovascular disease outcomes: An analysis of the Framingham Heart Study. , 2015, Journal of hepatology.

[301]  E. Bjornsson,et al.  Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. , 2015, Gastroenterology.

[302]  Yu Xu,et al.  Advanced fibrosis associates with atherosclerosis in subjects with nonalcoholic fatty liver disease. , 2015, Atherosclerosis.

[303]  M. Moriguchi,et al.  Lower levels of insulin‐like growth factor‐1 standard deviation score are associated with histological severity of non‐alcoholic fatty liver disease , 2015, Hepatology research : the official journal of the Japan Society of Hepatology.

[304]  H. O'Connor,et al.  Effect of aerobic exercise training dose on liver fat and visceral adiposity. , 2015, Journal of hepatology.

[305]  Mary E Rinella,et al.  Nonalcoholic fatty liver disease: a systematic review. , 2015, JAMA.

[306]  C. Sirlin,et al.  Magnetic resonance imaging and liver histology as biomarkers of hepatic steatosis in children with nonalcoholic fatty liver disease , 2015, Hepatology.

[307]  A. Burt,et al.  Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. , 2015, Journal of hepatology.

[308]  Mats Fredrikson,et al.  Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up , 2015, Hepatology.

[309]  Vincent Wai-Sun Wong,et al.  Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study , 2015, Gut.

[310]  Barry J. Davis,et al.  Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials , 2015, The Lancet.

[311]  G. Deutsch,et al.  Hepatic Steatosis Is Prevalent in Stillborns Delivered to Women With Diabetes Mellitus , 2015, Journal of pediatric gastroenterology and nutrition.

[312]  K. C. Petri,et al.  Comparable Liraglutide Pharmacokinetics in Pediatric and Adult Populations with Type 2 Diabetes: A Population Pharmacokinetic Analysis , 2015, Clinical Pharmacokinetics.

[313]  K. Cusi,et al.  The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease , 2015, Hepatology.

[314]  K. Cusi,et al.  High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels. , 2014, The Journal of clinical endocrinology and metabolism.

[315]  Y. Graham,et al.  Routine Liver Biopsy During Bariatric Surgery: an Analysis of Evidence Base , 2015, Obesity Surgery.

[316]  D. Ryan,et al.  Weight-Loss Therapy in Type 2 Diabetes: Effects of Phentermine and Topiramate Extended Release , 2014, Diabetes Care.

[317]  G. Bray,et al.  American association of clinical endocrinologists and american college of endocrinology position statement on the 2014 advanced framework for a new diagnosis of obesity as a chronic disease. , 2014, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[318]  V. Mohan,et al.  Clinical profile of nonalcoholic Fatty liver disease among young patients with type 1 diabetes mellitus seen at a diabetes speciality center in India. , 2014, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[319]  A. Suzuki,et al.  Prevalence and natural history of histologically proven chronic liver disease in a longitudinal cohort of patients with type 1 diabetes , 2014, Hepatology.

[320]  H. Völzke,et al.  Association of Non-alcoholic Fatty Liver Disease with Chronic Kidney Disease: A Systematic Review and Meta-analysis , 2014, PLoS medicine.

[321]  C. Bouchard,et al.  Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. , 2014, JAMA.

[322]  G. Roglić,et al.  Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study. , 2014, The lancet. Diabetes & endocrinology.

[323]  C. Sirlin,et al.  Evidence and recommendations for imaging liver fat in children, based on systematic review. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[324]  S. Anderson,et al.  Bariatric surgery and its impact on cardiovascular disease and mortality: a systematic review and meta-analysis. , 2014, International journal of cardiology.

[325]  R. Henry,et al.  Prevention of Type 2 Diabetes in Subjects With Prediabetes and Metabolic Syndrome Treated With Phentermine and Topiramate Extended Release , 2014, Diabetes Care.

[326]  J. Fallowfield,et al.  Using non-invasive biomarkers to identify hepatic fibrosis in people with type 2 diabetes mellitus: the Edinburgh type 2 diabetes study. , 2014, Journal of hepatology.

[327]  M. Ngu,et al.  Systematic review with meta‐analysis: non‐invasive assessment of non‐alcoholic fatty liver disease – the role of transient elastography and plasma cytokeratin‐18 fragments , 2014, Alimentary pharmacology & therapeutics.

[328]  C. Catalano,et al.  Left ventricular dysfunction in obese children and adolescents with nonalcoholic fatty liver disease , 2014, Hepatology.

[329]  A. Feldstein,et al.  The Evaluation of Hepatic Fibrosis Scores in Children with Nonalcoholic Fatty Liver Disease , 2013, Digestive Diseases and Sciences.

[330]  W. Garvey,et al.  The Progression of Cardiometabolic Disease: Validation of a New Cardiometabolic Disease Staging System Applicable to Obesity , 2013, Obesity.

[331]  G. Ward,et al.  The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. , 2013, Journal of hepatology.

[332]  G. Musso,et al.  Association of obstructive sleep apnoea with the presence and severity of non-alcoholic fatty liver disease. A systematic review and meta-analysis.. OBESITY , 2022 .

[333]  A. Scherzinger,et al.  Intrahepatic fat is increased in the neonatal offspring of obese women with gestational diabetes. , 2013, The Journal of pediatrics.

[334]  D. Blackhurst,et al.  Bariatric surgery is associated with a reduction in major macrovascular and microvascular complications in moderately to severely obese patients with type 2 diabetes mellitus. , 2013, Journal of the American College of Surgeons.

[335]  Miriam B. Vos,et al.  Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents, 1988-1994 to 2007-2010. , 2013, The Journal of pediatrics.

[336]  J. Stoker,et al.  Accuracy of prediction scores and novel biomarkers for predicting nonalcoholic fatty liver disease in obese children , 2013, Obesity.

[337]  A. Dhawan,et al.  Transient Elastography Is a Useful Noninvasive Tool for the Evaluation of Fibrosis in Paediatric Chronic Liver Disease , 2013, Journal of pediatric gastroenterology and nutrition.

[338]  A. Feldstein,et al.  Combined paediatric NAFLD fibrosis index and transient elastography to predict clinically significant fibrosis in children with fatty liver disease , 2013, Liver international : official journal of the International Association for the Study of the Liver.

[339]  Bin Wang,et al.  Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis. , 2013, Biomedical reports.

[340]  G. Shaibi,et al.  Ethnicity and elevated liver transaminases among newly diagnosed children with type 2 diabetes , 2012, BMC Pediatrics.

[341]  C. Boesch,et al.  Effects of Aerobic Versus Resistance Exercise Without Caloric Restriction on Abdominal Fat, Intrahepatic Lipid, and Insulin Sensitivity in Obese Adolescent Boys , 2012, Diabetes.

[342]  K. Ho,et al.  Intragastric balloon significantly improves nonalcoholic fatty liver disease activity score in obese patients with nonalcoholic steatohepatitis: a pilot study. , 2012, Gastrointestinal endoscopy.

[343]  R. Kitazawa,et al.  Nonalcoholic fatty liver disease in adult hypopituitary patients with GH deficiency and the impact of GH replacement therapy. , 2012, European journal of endocrinology.

[344]  S. Klein,et al.  Randomized trial of exercise effect on intrahepatic triglyceride content and lipid kinetics in nonalcoholic fatty liver disease , 2012, Hepatology.

[345]  V. de Lédinghen,et al.  Screening for liver fibrosis by using FibroScan(®) and FibroTest in patients with diabetes. , 2012, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[346]  J. Hardies,et al.  Prevalence of Prediabetes and Diabetes and Metabolic Profile of Patients With Nonalcoholic Fatty Liver Disease (NAFLD) , 2012, Diabetes Care.

[347]  G. Musso,et al.  Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials , 2012, Diabetologia.

[348]  Eliseo Guallar,et al.  Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: A meta‐analysis , 2011, Hepatology.

[349]  K. Cusi,et al.  Role of ethnicity in overweight and obese patients with nonalcoholic steatohepatitis , 2011, Hepatology.

[350]  Jimmy D Bell,et al.  The Influence of Maternal Body Mass Index on Infant Adiposity and Hepatic Lipid Content , 2011, Pediatric Research.

[351]  N. Chalasani,et al.  Endpoints and clinical trial design for nonalcoholic steatohepatitis , 2011, Hepatology.

[352]  Sarah A. Moore,et al.  Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss , 2011, Gut.

[353]  V. Wong,et al.  Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease , 2011, Gut.

[354]  J. Schulz-Menger,et al.  Randomized comparison of reduced fat and reduced carbohydrate hypocaloric diets on intrahepatic fat in overweight and obese human subjects , 2011, Hepatology.

[355]  P. Rosenthal,et al.  Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. , 2011, JAMA.

[356]  Devjit Tripathy,et al.  Pioglitazone for diabetes prevention in impaired glucose tolerance. , 2011, The New England journal of medicine.

[357]  E. Bonora,et al.  Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes. , 2010, Journal of hepatology.

[358]  S. Caprio,et al.  Central Role of Fatty Liver in the Pathogenesis of Insulin Resistance in Obese Adolescents , 2010, Diabetes Care.

[359]  D. Reboussin,et al.  Effect of a 12-Month Intensive Lifestyle Intervention on Hepatic Steatosis in Adults With Type 2 Diabetes , 2010, Diabetes Care.

[360]  G. Musso,et al.  A meta‐analysis of randomized trials for the treatment of nonalcoholic fatty liver disease , 2010, Hepatology.

[361]  B. Neuschwander‐Tetri,et al.  Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. , 2010, The New England journal of medicine.

[362]  E. Jackvony,et al.  Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis , 2010, Hepatology.

[363]  B. Neuschwander‐Tetri,et al.  Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial , 2009, Hepatology.

[364]  J. Hoofnagle,et al.  Clinical trial: pilot study of metformin for the treatment of non‐alcoholic steatohepatitis , 2009, Alimentary pharmacology & therapeutics.

[365]  R. Holman,et al.  10-year follow-up of intensive glucose control in type 2 diabetes. , 2008, The New England journal of medicine.

[366]  G. Aithal,et al.  Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. , 2008, Gastroenterology.

[367]  Alexander Pertsemlidis,et al.  Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease , 2008, Nature Genetics.

[368]  F. Marra,et al.  Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis , 2008, Hepatology.

[369]  Amalia Gastaldelli,et al.  Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. , 2007, Gastroenterology.

[370]  P. Raskin,et al.  Effect of insulin-metformin combination on hepatic steatosis in patients with type 2 diabetes. , 2007, Journal of diabetes and its complications.

[371]  A. Häkkinen,et al.  Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes. , 2007, American journal of physiology. Endocrinology and metabolism.

[372]  J. Hardies,et al.  A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. , 2006, The New England journal of medicine.

[373]  J. Lindström,et al.  Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study , 2006, The Lancet.

[374]  M. Leshno,et al.  Double-Blind Randomized Placebo-Controlled Trial of Orlistat or the Treatment of Nonalcoholic Fatty Liver Disease , 2022 .

[375]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[376]  K. Nadeau,et al.  Type 2 Diabetes in Children is Frequently Associated with Elevated Alanine Aminotransferase , 2005, Journal of pediatric gastroenterology and nutrition.

[377]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[378]  G. Marchesini,et al.  A Randomized Controlled Trial of Metformin versus Vitamin E or Prescriptive Diet in Nonalcoholic Fatty Liver Disease , 2005, The American Journal of Gastroenterology.

[379]  A. Zanella,et al.  Updated Definitions of Healthy Ranges for Serum Alanine Aminotransferase Levels , 2002, Annals of Internal Medicine.

[380]  S. Fowler,et al.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002 .